Moderna projects improved 2025 financials, outlines 2026 growth, and details multiple pipeline catalysts
MRNA sits 59% above its 52-week low of $22.28.
Summary
Moderna provided preliminary positive financial results for 2025, reiterated 2026 revenue growth targets with further cost reductions, and highlighted numerous key pipeline milestones expected in 2026.
Key Events · Product Development and Regulatory · MRNA
-
Preliminary 2025 Financials Exceed Expectations
Moderna reported approximately $1.9 billion in unaudited revenue for fiscal year 2025, exceeding the midpoint of its previously communicated range. GAAP operating expenses for 2025 are expected to be $5.0 - $5.2 billion, an improvement of $200 million from prior guidance.
-
Positive 2026 Financial Outlook and Cost Reductions
The company reiterated its target of up to 10% revenue growth in 2026 and projected further GAAP operating expense reductions to approximately $4.9 billion. Moderna aims for cash breakeven by 2028.
-
Strong Cash Position and New Financing
Moderna ended 2025 with approximately $8.1 billion in unaudited cash, cash equivalents, and investments, which includes a $0.6 billion drawdown from a recently closed $1.5 billion five-year term loan facility.
-
Multiple Key Pipeline Catalysts Expected in 2026
The company anticipates potential first approvals for its seasonal flu and flu/COVID combination vaccines in 2026. Additionally, pivotal trial data readouts are expected for its RSV vaccine, oncology candidates (melanoma), and rare disease therapeutics (Propionic Acidemia).
Analysis · MRNA · Life Sciences
Moderna's comprehensive update at the J.P. Morgan Healthcare Conference signals a strong operational and strategic outlook. The company exceeded its 2025 revenue midpoint and significantly improved operating expense guidance, demonstrating effective cost management. The reiteration of 2026 revenue growth and further expense reductions, alongside a target for cash breakeven by 2028, provides a clear path to profitability. Crucially, the extensive list of potential product approvals and pivotal trial data readouts across its seasonal vaccine, oncology, and rare disease portfolios in 2026 indicates a year rich with catalysts that could drive future growth and market expansion. The robust cash position, supported by a new term loan and external funding for a vaccine candidate, further strengthens the company's financial flexibility to execute on its pipeline.
At the time of this filing, MRNA was trading at $35.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $22.28 to $47.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.